These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30732487)

  • 1. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
    Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
    J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
    Lin Z; Xuan J
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):549-557. PubMed ID: 32757968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco.
    Tazi A; Errachidi F; Sonawane D; Tahri G; Rao S; Mehta S
    Ann Gen Psychiatry; 2024 Sep; 23(1):33. PubMed ID: 39294740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
    Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
    Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System.
    Soares Santos A; de Souza Noronha KVM; Viegas Andrade M; Mariano Ruas C
    J Ment Health Policy Econ; 2020 Mar; 23(1):27-37. PubMed ID: 32458815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.
    Yi ZM; Men P; Qu S; Li C; Yu X; Zhai S
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):313-320. PubMed ID: 32293194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
    Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
    Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
    Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
    Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
    Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
    Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
    Zeidler J; Mahlich J; Greiner W; Heres S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
    Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
    Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
    Kasteng F; Eriksson J; Sennfält K; Lindgren P
    Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
    Liu J; Cao L; Wu J
    Front Public Health; 2022; 10():987408. PubMed ID: 36187655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of paliperidone extended release in Spain.
    Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
    J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
    Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
    Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.